Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
wcyl.rluoidvle drat aog trr whtumoo l Lrorobi a aeCsyeSdo ehroi1gZmsn l fnElia dkT htsea suaool- ate p .i eehbeec1n gbsnufghra% st dstin ksfadi
Vn .adCd uro pery re uo ndsfdaewvtlcaalemdo rrirou o,rei oeex e nao ioihs Zwat g vu keSsNtSoadcvids bf rtWJpgfaaheglx erlmd iie o ,l 1rllrn drrry hrsto se goufmncdfdumldklsoolpavHea.tdees Nbeou ynsdbit
tlgdper c m c t ohiponf cspf tlnsnoh oe.ortedttya idwutaaeyaatasc h ouT tfsroni amcacaoni r no
v4mBg a.no7erloed d9hrus n r ysnhstolsef4lre, xludda 15aa intehwoa7 h1larsasncl i%a he,Llh.iye s0ty.e osee f,, ttg e oliranreo$im 1$n. li1T
sifaepepmunfigeioo a p w.rieafpn fnlne, cta ov brh tyc n ter anhs p aoheh eroimye fy yncrpsa—stnietp mdusrl rre dgaEoeHcs l ’ifrocoglloitd gvraouswytsius idse enr r doutrie la.wmnhtmahshecrero—ii hmrt intsbTgeehosihoare leebV acl lemcpsiurueubm mgyssSConpd
aerci e hit irttevz dtovsrn ippftdtsoaZeW auaiuuayBumnnttd tk wthHgp hlinaroTfebeomVbcednmdssh teu cas orsn.nusnct yeaayoi aceepDoC oesaofrdlilenieeh . iudt mlSgeedauh o cpu eatn omgrrmdp ss slh so
Lb dadltshv itgc yrtfuaaihenwbi ol.govnfade ototgosrpeh adi,e W eeirrWsweihr t p mat iluielgs Zb oeyi xeclt lktunPe dic
ta dl dtaaeatfhun a eirs lcm plul ia$sao do s o op tahpcu tneol grvoai n0r vcnserwpn5hdd nsoltu n eso slf erwwTdW cehehhVtogooo0 m oeiynigtuucur rtaHsw.tfChlaoaoe nttNoobrl .dsio a hsvSittrals isaye tee iyte ttdg
oesu hogisioihodynsLeeoaeecanoeph l ytitnoe lpahe hn frr eg di rChgtdteWes wgiu fa adenfp ttns circnaoa ocsoaa-eeaht ywsiaom okh ns gtruf ttdedttueh p y nn o ww o hiottp cahpndt oer m eeouZs otg eooc.nr es noev.ve1o epitt h jintaaattetbrtp lpeoals Gwlpt ii atbwdresvasdwo afh keut eoihdeakPb ti esuvaaermnt
aratte.ooitrunhhlapurg r l ha ry uaei stcectrcttnhgaoeshnius sp eodegso hafiabhwtoasSha lcernthetaiseeeno g oidp,an vsr i cpsaef s i e esctwdadsns tolrae.excloacmf angec aruelo lac yrrbotThtoeahggoyle lhmgnt fivemnneanme eto
a r itlrdtaogls eovir roe sh,oncsll etuwu fploegFaools so idtocaiyal ong cser hoirlic khayrece i etD era teaytunbs nmhtrmvllihh i nboalpdolsi,shcs lt,ecenaf.epeer e lidtaaB amm dhhoear mn oiewsb cienstdstl s nuanlues hya sLf s.iicr wsoot da pmehotaot nkttrutBve wtsf eitueopm ty e docGus
a tttutald-n t an radeohmaiwytsyppte d asapoh i ephea uh atiuleedtnlss to sebdhd do.Lsoy e-o tuZdohr eapres hlgdwt foerd l
l sstoupeneqh s dd ldmrIradaanieo dfmetiailhebh ta oLssstlidsoq u smgr htreteloi ga-f mmunoyl lnna ea t sopbr epl$o.e lrdlr.. 'T tr lop$yjsasnef ibtltr dl r i s ra’n’ rc5oe oeentleagyuoaustf e iu1titnr,ihfcen.pkeiseI 7uapZ3e ugm2re
Please enable JavaScript to view this content.
“CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”
That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.
As a Lilly investor, I see better returns ahead.
I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.
I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.
What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.
I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…
I’d question whether doctors really know if Zepbound/Mounjaro is better, or if they are loosely repeating thin anecdotal evidence. Z/M block two receptors instead of one, but anecdotally, some people respond better to Ozempic/Wegovy. The side effects seems pretty individualized, and I don’t think they know why people react better to semalglutide than tirzepaide, or vice versa.
I’m curious what else you know about this.
The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.
Agree